Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid

Neuropharmacology

Volumn 39, Issue 12, 2000, Pages 2352-2359

  Balcioglu, Aygul ^a   Wurtman, Richard J ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Dopamine; Hypothalamus; Serotonin; Sibutramine; Striatum

Indexed keywords

DOPAMINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; EXTRACELLULAR FLUID; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOTHALAMUS; MALE; MICRODIALYSIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

AMPHETAMINE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOBUTANES; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; ELECTROCHEMISTRY; EXTRACELLULAR SPACE; HYPOTHALAMUS; MALE; MICRODIALYSIS; NEOSTRIATUM; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; SYNAPTOSOMES;

EID: 0033894420     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(00)00083-6     Document Type: Article

References (37)

1. Benloucif S., Keegan M.J., Galloway M.P. Serotonin facilitated the dopamine release in vivo: pharmacological characterization. Journal of Pharmacology and Experimental Therapeutics. 265:1993;373-377.
2. Bray G.A., Ryan D.H., Gordon D., Heidingsfelder S., Cerise F., Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obesity Research. 4(3):1996;263-270.
3. Buckett W.R., Thomas P.C., Luscombe G.P. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Progress in Neuropsychopharmacology and Biological Psychiatry. 12(5):1988;575-584.
4. 3H]5-HT uptake: effects of administration of various antidepressant treatments. Neuropharmacology. 32:1993;737-743.
5. Cheetham S.C., Kettle C.J., Martin K.F., Heal D.J. D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function. Journal of Neural Transmission, General Section. 102(1):1995;35-46.
6. Dodd P.R., Hardy J.A., Oakley A.E., Edwardson J.A., Perry E.K., Delaunoy J.P. A rapid method for preparing synaptosomes: comparison with alternative procedures. Brain Research. 226:1981;107-118.
7. Graybiel A.M., Ragsdale C.W. Fiber connections of the basal ganglia. Cuenod M., Kreutzberg G.W., Bloom F.E. Development and Chemical Specificity of Neurons. Vol. 51:1979;239-283 Elsevier/North-Holland Biomedical Press, Amsterdam.
8. Gundlah C., Martin K.F., Heal D.J., Auerbach S.B. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. Journal of Pharmacology and Experimental Therapeutics. 283:1997;581-591.
9. Heal D.J., Butler S.A., Hurst E.M., Buckett W.R. Antidepressant treatments, including sibutramine hydrochloride and electroconvulsive shock, decrease beta 1- but not beta 2-adrenoceptors in rat cortex. Journal of Neurochemistry. 53(4):1989;1019-1025.
10. Heal D.J., Frankland A.T., Buckett W.R. A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain. Neuropharmacology. 29:1990;1141-1150.
11. Heal D.J., Prow M.R., Buckett W.R. Effects of antidepressant drugs and electroconvulsive shock on pre- and postsynaptic alpha 2-adrenoceptor function in the brain: rapid down-regulation by sibutramine hydrochloride. Psychopharmacology (Berlin). 103(2):1991;251-257.
12. Heal D.J., Prow M.R., Gosden J., Luscombe G.P., Buckett W.R. A comparison of various antidepressant drugs demonstrates rapid desensitisation of alpha 2-adrenoceptors exclusively by sibutramine hydrochloride. Psychopharmacology (Berlin). 107(4):1992;497-502.
13. Heal D.J., Frankland A.T.J., Gosden J., Hutchins L.J., Prow M.R., Luscombe G.P.et al. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacology. 107:1992;303-309.
14. Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. Journal of Receptor Research. 8:1988;59-81.
15. Jackson H.C., Bearham M.C., Hutchins L.J., Mazurkiewicz S.E., Needham A.M., Heal D.J. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. British Journal of Pharmacology. 121(8):1997;1613-1618.
16. Jackson H.C., Needham A.M., Hutchins L.J., Mazurkiewicz S.E., Heal D.J. Comparison of the effect of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. British Journal of Pharmacology. 121(8):1997;1758-1762.
17. 2C/2B receptor antagonist. British Journal of Pharmacology. 111:1994;797-802.
18. Larsen P.J., Hay-Schmidt A., Vrang N., Mikkelsen J.D. Origin of projections from the midbrain raphe nuclei to the hypothalamic paraventricular nucleus in the rat: a combined retrograde and anterograde tracing study. Neuroscience. 70(4):1996;963-988.
19. Lean M.E. Sibutramine - a review of clinical efficacy. International Journal of Obesity and Related Metabolic Disorders. 21(Suppl. 1):1997;S30-S36.
20. Lindvall O., Bjorklund A., Skagerberg G. Selective histochemical demonstration of dopamine terminal systems in rat di- and telencephalon: new evidence for dopaminergic innervation of hypothalamic neurosecretory nuclei. Brain Research. 306(1-2):1984;19-30.
21. Leysen J.E., Awouters F., Kennis L., Laduron P.M., Vandenberk J., Janssen P.A.J. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sciences. 28:1981;1015-1022.
22. Leysen J.E., Gommeren W., Gompel P.V., Wynants J., Janssen P.F.M., Laduron P.M. Receptor-binding properties in vitro and in vivo of ritanserin, a very potent and long acting serotonin-S2 antagonist. Molecular Pharmacology. 27:1985;600-611.
23. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry. 193:1951;265-275.
24. Luscombe G.P., Hopcroft R.H., Thomas P.C., Buckett W.R. The contribution of metabolites to the rapid and potent down-regulation of rat cortical ß-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology. 28:1989;129-134.
25. Luscombe G.P., Slater N.A., Lyons M.B., Wynne R.D., Scheinbaum M.L. Effects on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl. Psychopharmacology (Berlin). 100(3):1990;345-349.
26. Martin K.F., Phillips I., Cheetham S.C., Heal D.J. Dopamine D2 receptors; a potential pharmacological target for nomifensine and tranylcypromine but not other antidepressant treatments. Pharmacology, Biochemistry and Behavior. 51(4):1995;565-569.
27. Matsumoto M., Yoshioka M., Togashi H., Saito H. Dopamine receptor regulation of serotonin release from the rat hippocampus measured by in vivo microdialysis. Journal of Neurochemistry. 65:1995;S29.
28. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd edn:1986;Academic Press, Sydney.
29. Prow M.R., Hannon S.D., Aspley S., Martin K.F., Heal D.J. Comparison of the effects of sibutramine, fluoxetine and d-fenfluramine on extracellular 5-HT in rat anterior hypothalamus: an in vivo microdialysis study. British Journal of Pharmacology. 120:1996;351P.
30. Ryan D.H., Kaiser P., Bray G.A. Sibutramine; a novel new agent for obesity treatment. Obesity Research. 3(Suppl. 4):1995;553S-559S.
31. Samanin R., Garattini S. Neurochemical mechanism of action of anorectic drugs. Pharmacology and Toxicology. 73:1993;63-68.
32. Sawyer C.H., Clifton D.K. Aminergic innervation of the hypothalamus. Federation Proceedings. 39(11):1980;2889-2895.
33. Steinbusch H.W., van der Kooy D., Verhofstad A.A., Pellegrino A. Serotonergic and non-serotonergic projections from the nucleus raphe dorsalis to the caudate-putamen complex in the rat, studied by a combined immunofluorescence and fluorescent retrograde axonal labeling technique. Neuroscience Letters. 19:1980;137-142.
34. Tossman U., Ungerstedt U. Microdialysis in the study of extracellular levels of aminoacids in the rat brain. Acta Physiologica Scandinavica. 128:1986;9-14.
35. van Bockstaele E.J., Pickel V.M. Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interaction with catecholamine afferents. Journal of Comparative Neurology. 334:1993;603-617.
36. van der Kooy D., Hattori T. Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labeling in the rat. Brain Research. 186:1980;1-7.
37. Weintraub M., Rubio A., Golic A., Byrne L., Scheinbaum M.L. Sibutramine in weight control: a dose-ranging, efficacy study. Clinical Pharmacology and Therapeutics. 50(3):1991;330-337.